DIAGNOS Inc. Stock

Equities

ADK

CA2524423068

IT Services & Consulting

Market Closed - Toronto S.E. 03:59:47 2024-04-24 pm EDT 5-day change 1st Jan Change
0.295 CAD -1.67% Intraday chart for DIAGNOS Inc. -3.28% -27.16%
Sales 2024 * 258K 188K Sales 2025 * 5.83M 4.26M Capitalization 22.61M 16.52M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 87.6 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.88 x
P/E ratio 2024 *
-5.9 x
P/E ratio 2025 *
-14.8 x
Employees 22
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.77%
More Fundamentals * Assessed data
Dynamic Chart
DIAGNOS Inc. to Expedite Application for Medical Device License to Health Canada and US FDA Related to its 4 New Analysis Modules, and is Planning ISO 27001 Certification CI
DIAGNOS Inc. Appoints Philippe Couillard to Its Board of Directors CI
Diagnos Raises C$182,000 in the Final Tranche of a Private Placement of Share Units MT
DIAGNOS Inc. announced that it has received CAD 0.578 million in funding CI
Diagnos Announces Grant Of Stock Options MT
DIAGNOS Inc. Appoints Michael Braeuel to Board of Directors CI
DIAGNOS Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
DIAGNOS Announces Closing Of First Tranche Of Private Placement MT
DIAGNOS Inc. announced that it expects to receive CAD 1.19244 million in funding CI
Diagnos Inc. Appoints Yves-Stéphane Couture as Chief Operating Officer CI
Diagnos Secures Exclusive Distribution Agreement for Canada with EssilorLuxottica MT
Diagnos Inc. Secures Exclusive Distribution Agreement for Canada with Essilorluxottica CI
DIAGNOS Inc. announced that it has received CAD 0.640051 million in funding CI
DIAGNOS Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
DIAGNOS Inc. Announces Commencement of its Innovative Deployment in an Advanced Screening Program At Canada's Presented Specialist Care Provider in Diabetes and Endocrinology CI
More news
1 day-1.67%
1 week-3.28%
Current month+25.53%
1 month+20.41%
3 months-11.94%
6 months-37.89%
Current year-27.16%
More quotes
1 week
0.28
Extreme 0.28
0.32
1 month
0.23
Extreme 0.23
0.35
Current year
0.23
Extreme 0.23
0.43
1 year
0.23
Extreme 0.23
0.59
3 years
0.13
Extreme 0.125
0.65
5 years
0.10
Extreme 0.1
0.77
10 years
0.10
Extreme 0.1
2.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 00-09-20
Director of Finance/CFO - 08-04-30
Chief Operating Officer - 16-12-31
Members of the board TitleAgeSince
Director/Board Member - 19-11-26
Chief Executive Officer - 00-09-20
Chairman 59 20-09-27
More insiders
Date Price Change Volume
24-04-24 0.295 -1.67% 45,500
24-04-23 0.3 +1.69% 51,337
24-04-22 0.295 -4.84% 105,500
24-04-19 0.31 +3.33% 36,000
24-04-18 0.3 -1.64% 48,500

Delayed Quote Toronto S.E., April 24, 2024 at 03:59 pm EDT

More quotes
DIAGNOS Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for modifying and developing of applications, such as Computer Assisted Retina Analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. Its geographical areas include Canada, the United States, Saudi Arabia, Mexico, Costa Rica and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.295 CAD
Average target price
1.5 CAD
Spread / Average Target
+408.47%
Consensus